


Curriculum Vitae

Name	Joan S Brugge		
Current Position & Affiliation	7/97-present	Professor Harvard Medical School Department of Cell Biology	
	1/15- present	Director Ludwig Center at Harvard	
Country	United States of America		

Educational Background

- 1971 Northwestern University, Evanston, IL
B.A. in Biology, with honors (minor in Chemistry)
- 1975 Baylor College of Medicine, Houston, TX
Ph.D. in Virology Adviser: Dr. Janet Butel

Professional Experience

- 1975-79 Postdoctoral Fellow
University of Colorado Medical Center
Denver, CO
Adviser: Dr. Raymond Erikson
- 7/79 - 6/84 Assistant Professor
Department of Microbiology
State University of New York at Stony Brook
Stony Brook, NY 11794
- 7/84 - 12/87 Associate Professor
Department of Microbiology
State University of New York at Stony Brook
Stony Brook, NY 11794
- 1/88 - 12/88 Professor
Department of Microbiology
State University of New York at Stony Brook
Stony Brook, NY 11794

- 1/89 - 5/92 Investigator
Howard Hughes Medical Institute
Professor
Department of Microbiology
University of Pennsylvania
- 5/92 - 9/96 Scientific Director
Senior Vice President, Research and Biology
ARIAD Pharmaceuticals, Inc.
- 10/96 - 7/97 Senior Vice President, Exploratory Research
ARIAD Pharmaceuticals, Inc.
- 7/03 - 07/04 Acting Chair
Harvard Medical School
Department of Cell Biology
- 7/04 – 12/14 Chair
Department of Cell Biology
Harvard Medical School

Professional Organizations

American Association for Cancer Research
American Society of Clinical Oncology
American Society for Microbiology
National Academy Society
National Academy of Medicine
American Academy of Arts and Science

Main Scientific Publications

Takahashi N, Chen H-Y, Harris IS, Stover D, Bronson RT, Takemura RT, Kitao A, Deraedt T, Cichowski K, Welm AL, Mori, Y, Mills GB, Brugge JS. Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. 2018. Cancer Cell 33: 6, p985-1003.
<https://doi.org/10.1016/j.ccell.2018.05.001>

Iavarone, C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Levenson JD, Sampath D, Mills GB, Brugge JS. Combined MEK and BCL-2/XL inhibition is effective in high-grade serous ovarian

cancer patient-derived xenograft models and BIM levels are predictive of responsiveness. *Mol. Cancer Therapeutics* 2019 Mar;18(3):642-655. PMID:30679390

ZoellerJJ, VagodnyA, TanejaK, TanBY, O'BrienN, SlamonDJ, SampathD, Levenson JD, Bronson RT, Dillon DA, Brugge JS, Neutralization of BCL-2/XL enhances the cytotoxicity of T-DM1 in vivo *Mol Cancer Ther.* 2019 Jun;18(6):1115-1126.

Zervantonakis IK, Poskus MD, Scott AL, Selfors LM, Lin J, Dillon DA, Pathania S, Sorger PK, Mills JB, Brugge JS, Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and anti-apoptotic pathways *Proc Natl Acad Sci USA* 2020 Jul 14;117(28):16500-16508 PMID: 32601199

Rosenbluth JM, Schackmann RCJ, Gray GK, Selfors LM, Li CM, Boedicker M, Kuiken HJ, Richardson A, Brock J, Garber J, Dillon D, Sachs N, Clevers H, Brugge JS Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. *Nat Commun.* 2020 Apr 6;11(1):1711. doi: 10.1038/s41467-020-15548-7.PMID: 32249764

Amara SN, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K, Panayiotou R, Foster R, Rueda BR, Aktipis A, Spellman P, Ince TA, Joanne X, Oberley M, Gatalica Z, Nicholas Navin N, Mills GB, Bronson RT, Joan S. Brugge JS, Transient Commensal Clonal Interactions Can Drive Tumor Metastasis, *Nat Commun* 2020 Nov 16;11(1):5799 PMID: 33199705

Takahashi N, Cho P, Selfors LM, Kuiken HL, Kaul R, Harris IS, Zhang T, Gygi SP, Brugge JS, 3D Tissue Culture Model Coupled with CRISPR Screens Reveals NRF2 Hyperactivation as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Protection from Ferroptosis, *Mol Cell* 2020 Dec 3;80(5):828-844 PMID: 33128871
